Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Immuneering Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 END-OF-PHASE 2 INTERACTIONS WITH FDA COMPLETE; SCIENTIFIC ADVICE RECEIVED FROM EMA   COMPANY EXPECTS TO DOSE FIRST PATIENT IN GLOBAL PHASE 3 REGISTRATIONAL TRIAL, MAPKEEPER 301, IN MID-2026   OVERALL SURVIVAL UPDATE FOR PHASE 2A TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS PLANNED IN COMING WEEKS  NEW YORK, DEC. 17, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A LATE-STAGE CLINICAL ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE AND HELPING THEM THRIVE, TODAY ANNOUNCED THAT IT IS ON TRACK TO DOSE THE FIRST PATIENT IN ITS PLANNED GLOBAL PHASE 3 REGISTRATIONAL TRIAL IN FIRST LINE PANCREATIC CANCER PATIENTS IN MID-2026, EVALUATING ATEBIMETINIB (320 MG QD) IN COMBINATION WITH MODIFIED GEMCITABINE AND NAB-PACLITAXEL (MGNP), COMPARED WITH GEMCITABINE AND NAB-PACLITAXEL (GNP) ALONE. NOTABLY, THE COMPANY COMPLETED ITS END-OF-PHASE 2 (EOP2) INTERACTIONS WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) AND RECEIVED SCIENTIFIC ADVICE FROM THE EUROPEAN MEDICINES AGENCY (EMA).

IMMUNEERING ADVANCES TOWARDS DOSING FIRST PATIENT IN PHASE 3 ATEBIMETINIB TRIAL FOR FIRST-LINE METASTATIC PANCREATIC CANCER PATIENTS, SECURING ALIGNMENT WITH FDA AND EMA

NEW YORK, DEC. 16, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A LATE-STAGE CLINICAL ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE AND HELPING THEM THRIVE, TODAY ANNOUNCED THAT IT IS EXPECTED TO BE ADDED TO THE NASDAQ BIOTECHNOLOGY INDEX (NBI) (NASDAQ: NBI). IMMUNEERING'S ADDITION WILL BECOME EFFECTIVE PRIOR TO MARKET OPEN ON MONDAY, DECEMBER 22, 2025.

IMMUNEERING TO BE ADDED TO THE NASDAQ BIOTECHNOLOGY INDEX (NBI)

NEW YORK, NOV. 25, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE AND HELPING THEM THRIVE, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE IN NEW YORK CITY. PARTICIPATING WILL BE BEN ZESKIND, CO-FOUNDER AND CHIEF EXECUTIVE OFFICER, IGOR MATUSHANSKY M.D.

IMMUNEERING TO PRESENT AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

- ANNOUNCED EXTRAORDINARY 86% OVERALL SURVIVAL AT 9 MONTHS IN FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP -

IMMUNEERING REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS AND CLINICAL UPDATES

- NEW CASE STUDIES ON FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB IN COMBINATION WITH FOLFIRINOX TO BE SHARED BY TRIAL INVESTIGATORS  - CONFERENCE CALL SCHEDULED FOR WEDNESDAY, NOVEMBER 12, 2025, AT 4:30 PM ET - NEW YORK, NOV. 04, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT THIRD QUARTER 2025 FINANCIAL RESULTS AND TRIAL INVESTIGATORS WILL PROVIDE CASE STUDIES FROM FIRST-LINE PANCREATIC CANCER PATIENTS TREATED IN THE COMPANY'S PHASE 2A STUDY OF ATEBIMETINIB IN COMBINATION WITH FOLFIRINOX, ON WEDNESDAY, NOVEMBER 12, 2025, AFTER THE CLOSE OF MARKET. IMMUNEERING WILL HOST A CONFERENCE CALL AND WEBCAST AT 1:30 PM PT / 4:30 PM ET ON THE SAME DAY.

IMMUNEERING TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDE NEW CLINICAL CASE STUDIES, ON WEDNESDAY, NOVEMBER 12, 2025

NEW YORK, SEPT. 26, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE, TODAY ANNOUNCED THAT IT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST AT 8:30 AM ET ON SEPTEMBER 29, 2025, TO DISCUSS RECENTLY ANNOUNCED UPDATED OVERALL SURVIVAL AND SAFETY DATA IN FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP (N=34) WITH 9 MONTHS MEDIAN FOLLOW UP.

IMMUNEERING TO DISCUSS RECENTLY ANNOUNCED OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON MONDAY, SEPTEMBER 29, 2025

IMMUNEERING ANNOUNCES PRICING OF $175 MILLION UNDERWRITTEN PUBLIC OFFERING OF CLASS A COMMON STOCK AND CONCURRENT $25 MILLION PRIVATE PLACEMENT OF CLASS A

IMMUNEERING ANNOUNCES PRICING OF $175 MILLION UNDERWRITTEN PUBLIC OFFERING OF CLASS A COMMON STOCK AND CONCURRENT $25 MILLION PRIVATE PLACEMENT OF CLASS A COMMON STOCK TO SANOFI

IMMUNEERING ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF CLASS A COMMON STOCK AND PRE-FUNDED WARRANTS AND PROPOSED CONCURRENT PLACEMENT TO SANOFI

IMMUNEERING ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF CLASS A COMMON STOCK AND PRE-FUNDED WARRANTS AND PROPOSED CONCURRENT PRIVATE PLACEMENT OF CLASS A COMMON STOCK AND CLASS B COMMON STOCK TO SANOFI

- 86% OVERALL SURVIVAL (OS) OBSERVED AT 9 MONTHS; STANDARD OF CARE BENCHMARK IS ~47% - - 53% PROGRESSION-FREE SURVIVAL (PFS) OBSERVED AT 9 MONTHS; STANDARD OF CARE BENCHMARK IS ~29% - - COMPANY EXPECTS REGULATORY FEEDBACK ON PIVOTAL TRIAL PLANS IN Q4 2025 AND, SUBJECT TO THAT FEEDBACK, EXPECTS TO INITIATE PIVOTAL TRIAL BY THE END OF 2025 AND BEGIN DOSING PATIENTS BY MID-2026 - NEW YORK, SEPT. 24, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE, TODAY ANNOUNCED POSITIVE UPDATED SURVIVAL AND SAFETY DATA FROM ITS ONGOING PHASE 2A TRIAL OF ATEBIMETINIB (IMM-1-104) IN COMBINATION WITH MODIFIED GEMCITABINE/NAB-PACLITAXEL (MGNP) IN FIRST-LINE PANCREATIC CANCER PATIENTS (N=34), WITH 9 MONTHS MEDIAN FOLLOW UP.

IMMUNEERING ANNOUNCES EXTRAORDINARY 86% OVERALL SURVIVAL AT 9 MONTHS IN FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP

NEW YORK, SEPT. 16, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE, TODAY ANNOUNCED THE APPOINTMENT OF THOMAS J.

Immuneering Corporation

IMRX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Immuneering Corporation

IMRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMRX